H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Kiora Pharmaceuticals to $2 from $3.50 and keeps a Buy rating on the shares. The analyst believes the partnership should provide Kiora with sufficient capital to complete the Phase 2 trial of KIO-301.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KPRX: